デフォルト表紙
市場調査レポート
商品コード
1672703

胃不全麻痺治療市場:薬剤クラス別、疾患適応症別、タイプ別、投与経路別、流通チャネル別、地域別

Gastroparesis Treatment Market, By Drug Class, By Disease Indication, By Type, By Route of Administration, By Distribution Channel, By Geography


出版日
ページ情報
英文 237 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
胃不全麻痺治療市場:薬剤クラス別、疾患適応症別、タイプ別、投与経路別、流通チャネル別、地域別
出版日: 2025年02月20日
発行: Coherent Market Insights
ページ情報: 英文 237 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

胃不全麻痺治療の世界市場は、2025年には83億3,000万米ドルと推定され、2032年には115億8,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR4.8%で成長すると予測されています。

レポート範囲 レポート詳細
基準年 2024 2025年の市場規模 83億3,000万米ドル
実績データ 2020年から2024年まで 予測期間 2025年から2032年
予測期間:2025年~2032年 CAGR: 4.80% 2032年の価値予測 115億8,000万米ドル
図.胃不全麻痺治療市場シェア(%)、2025年地域別
Gastroparesis Treatment Market-IMG1

世界の胃不全麻痺治療市場の成長は、糖尿病と特発性胃不全麻痺の有病率の上昇が牽引しています。胃不全麻痺(胃排出遅延)は、胃が内容物を空にするのに時間がかかりすぎる慢性疾患です。胃不全麻痺の患者は、食後に吐き気、嘔吐、腹部膨満感、満腹感を経験します。現在のところ、胃不全麻痺を治す治療法はなく、利用可能な治療法は症状の管理に重点を置いています。新薬開発に関連する研究開発活動の高まりは、市場の成長を促進する可能性があります。

市場力学:

世界の胃不全麻痺治療市場の成長は、糖尿病人口の増加、特発性胃不全麻痺の有病率の上昇、胃不全麻痺に対する人々や医師の意識の高まりなどの要因によってもたらされます。しかし、経口薬に伴う患者のコンプライアンス不良、効果的な治療法の入手不可能性、薬物療法の副作用などが市場成長の妨げとなる可能性があります。より優れた有効性と副作用の少ない新薬の開発は、市場に有利な成長機会をもたらす可能性があります。

本調査の主な特徴

本レポートでは、世界の胃不全麻痺治療市場を詳細に分析し、2024年を基準年とした予測期間(2025-2032年)の市場規模(10億米ドル)と年間平均成長率(CAGR%)を掲載しています。

また、さまざまなセグメントにわたる潜在的な収益機会を明らかにし、この市場の魅力的な投資提案マトリクスについて解説しています。

また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。

企業ハイライト、製品ポートフォリオ、主要なハイライト、業績、戦略などのパラメータに基づいて、世界の胃不全麻痺治療市場における主要企業プロファイルを掲載しています。

本調査の対象となる主要企業には、Abbott Laboratories、Medtronic、Mylan、Pfizer、Johnson &Johnson Services、Bausch Health、Antrotrans、Alembic Pharmaceuticalsなどが含まれます。

本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。

世界の胃不全麻痺治療市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。

利害関係者は、世界の胃不全麻痺治療市場の分析に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。

目次

第1章 調査の目的と前提条件

  • 調査目的
  • 前提条件
  • 略語

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー

第3章 市場力学、規制、動向分析

  • 市場力学
  • 影響分析
  • 主なハイライト
  • 規制シナリオ
  • 製品の発売/承認
  • PEST分析
  • PORTERの分析
  • 合併と買収のシナリオ

第4章 世界の胃不全麻痺治療市場、薬剤クラス別、2020年-2032年、(10億米ドル)

  • 消化管運動促進剤
  • 制吐薬
  • プロトンポンプ阻害剤
  • その他(ボツリヌス毒素注射など)

第5章 世界の胃不全麻痺治療市場、疾患適応症別、2020年-2032年、(10億米ドル)

  • 糖尿病性胃不全麻痺
  • 特発性胃不全麻痺
  • 術後胃不全麻痺

第6章 世界の胃不全麻痺治療市場、タイプ別、2020年-2032年、(10億米ドル)

  • OTC薬
  • 処方薬

第7章 世界の胃不全麻痺治療市場、投与経路別、2020年-2032年、(10億米ドル)

  • 経口
  • 注射剤
  • 鼻腔

第8章 世界の胃不全麻痺治療市場、流通チャネル別、2020年-2032年、(10億米ドル)

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 世界の胃不全麻痺治療市場、地域別、2020年-2032年(10億米ドル)

  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第10章 競合情勢

  • Evoke Pharma, Inc.
  • Processa Pharmaceuticals, Inc.
  • Neurogastrx, Inc.
  • Vanda Pharmaceuticals Inc.
  • ANI Pharmaceuticals, Inc.
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Otsuka Holdings Co., Ltd.
  • CinDome Pharma, Inc.
  • PTC Therapeutics
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Atlantic Healthcare
  • Salix Pharmaceuticals
  • Rhythm Pharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Medtronic plc
  • Bausch Health Companies Inc.
  • Sanofi S.A.

第11章 アナリストの推奨事項

第12章 参考文献と調査手法

  • 参考文献
  • 調査手法
  • 出版社について
目次
Product Code: CMI5123

Global Gastroparesis Treatment Market is estimated to be valued at USD 8.33 Bn in 2025 and is expected to reach USD 11.58 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.8% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 8.33 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 4.80% 2032 Value Projection: USD 11.58 Bn
Figure. Gastroparesis Treatment Market Share (%), By Region 2025
Gastroparesis Treatment Market - IMG1

Global gastroparesis treatment market growth is driven by rising prevalence of diabetes and idiopathic gastroparesis. Gastroparesis, or delayed stomach emptying, is a chronic disorder, in which the stomach takes too long to empty its contents. Patients suffering from gastroparesis experience nausea, vomiting, bloating and fullness after eating. Currently, there is no cure for gastroparesis and the available treatment options focus on managing the symptoms. Rising research and development activities related to new drug development can drive the market growth.

Market Dynamics:

Global gastroparesis treatment market growth is driven by factors such as increasing diabetic population, rising prevalence of idiopathic gastroparesis, growing awareness about gastroparesis among people and physicians. However, poor patient compliance associated with oral medication, non-availability of effective treatment and side effects of drug therapies can hamper the market growth. Development of novel drugs with better efficacy and less side effects can offer lucrative growth opportunities in the market.

Key features of the study:

This report provides in-depth analysis of the global gastroparesis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global gastroparesis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Abbott Laboratories, Medtronic, Mylan, Pfizer, Johnson & Johnson Services, Bausch Health, Antrotrans, Alembic Pharmaceuticals

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global gastroparesis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global gastroparesis treatment market

Detailed Segmentation-

  • Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
    • Prokinetic Agents
    • Antiemetic Drugs
    • Proton Pump Inhibitors
    • Others (Botulinum Toxin Injections, etc.)
  • Disease Indication Insights (Revenue, USD Bn, 2020 - 2032)
    • Diabetes Gastroparesis
    • Idiopathic Gastroparesis
    • Post-surgical Gastroparesis
  • Type Insights (Revenue, USD Bn, 2020 - 2032)
    • Over-the-Counter Drugs
    • Prescription Drugs
  • Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
    • Oral
    • Injectables
    • Nasal
  • Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Evoke Pharma, Inc.
    • Processa Pharmaceuticals, Inc.
    • Neurogastrx, Inc.
    • Vanda Pharmaceuticals Inc.
    • ANI Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Limited
    • GlaxoSmithKline plc
    • Otsuka Holdings Co., Ltd.
    • CinDome Pharma, Inc.
    • PTC Therapeutics
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Atlantic Healthcare
    • Salix Pharmaceuticals
    • Rhythm Pharmaceuticals, Inc.
    • Ironwood Pharmaceuticals, Inc.
    • Medtronic plc
    • Bausch Health Companies Inc.
    • Sanofi S.A.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Gastroparesis Treatment Market, By Drug Class
    • Global Gastroparesis Treatment Market, By Disease Indication
    • Global Gastroparesis Treatment Market, By Type
    • Global Gastroparesis Treatment Market, By Route of Administration
    • Global Gastroparesis Treatment Market, By Distribution Channel
    • Global Gastroparesis Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Gastroparesis Treatment Market, By Drug Class, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Prokinetic Agents
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Antiemetic Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Proton Pump Inhibitors
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Others (Botulinum Toxin Injections, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Gastroparesis Treatment Market, By Disease Indication, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Diabetes Gastroparesis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Idiopathic Gastroparesis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Post-surgical Gastroparesis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Gastroparesis Treatment Market, By Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021- 2032
    • Segment Trends
  • Over-the-Counter Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Prescription Drugs
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Gastroparesis Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Injectables
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Nasal
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Gastroparesis Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Gastroparesis Treatment Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021- 2032, e (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Drug Class, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Disease Indication, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

10. Competitive Landscape

  • Evoke Pharma, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Processa Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Neurogastrx, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vanda Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ANI Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Takeda Pharmaceutical Company Limited
  • GlaxoSmithKline plc
  • Otsuka Holdings Co., Ltd.
  • CinDome Pharma, Inc.
  • PTC Therapeutics
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Atlantic Healthcare
  • Salix Pharmaceuticals
  • Rhythm Pharmaceuticals, Inc.
  • Ironwood Pharmaceuticals, Inc.
  • Medtronic plc
  • Bausch Health Companies Inc.
  • Sanofi S.A.

11. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

12. References and Research Methodology

  • References
  • Research Methodology
  • About us